Novartis receives three FDA Breakthrough Therapy Designations for Ilaris
Novartis announced that the US FDA has granted three Breakthrough Therapy Designations for Ilaris® (canakinumab) to treat three rare types...
Novartis announced that the US FDA has granted three Breakthrough Therapy Designations for Ilaris® (canakinumab) to treat three rare types...
Almac Group, the global contract development and manufacturing organisation, is pleased to announce an expansion to its serialisation capabilities to...
Novartis announced that the US Food and Drug Administration (FDA) has granted three Breakthrough Therapy Designations for Ilaris® (canakinumab) to...
AstraZeneca announced that it has entered into a licensing agreement with Ironwood Pharmaceuticals for the exclusive US rights to Zurampic®...
Bristol-Myers Squibb Company announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Opdivo...
AstraZeneca and its global biologics research and development arm, MedImmune announced an integrated genomics initiative to transform drug discovery and...
The University of Chicago and AbbVie a global biopharmaceutical company, have entered into a five-year collaboration agreement designed to improve...
Merck, known as MSD outside the United States and Canada, announced that the U.S. FDA has granted Breakthrough Therapy Designation...
This whitepaper highlights some of the most advanced companies in their innovative approaches to trial recruitment. Witness first-hand 5 case...
Clariant, a leading speciality chemical company, broke ground for building its new manufacturing and healthcare packaging plant in Tamil Nadu,...
Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.